268 related articles for article (PubMed ID: 26198370)
1. Comparison of vancomycin and linezolid in patients with peripheral vascular disease and/or diabetes in an observational European study of complicated skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus.
Eckmann C; Nathwani D; Lawson W; Corman S; Solem C; Stephens J; Macahilig C; Li J; Charbonneau C; Baillon-Plot N; Haider S
Clin Microbiol Infect; 2015 Sep; 21 Suppl 2():S33-9. PubMed ID: 26198370
[TBL] [Abstract][Full Text] [Related]
2. Weight-based antibiotic dosing in a real-world European study of complicated skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus.
Lawson W; Nathwani D; Eckmann C; Corman S; Stephens J; Solem C; Macahilig C; Li J; Baillon-Plot N; Charbonneau C; Haider S
Clin Microbiol Infect; 2015 Sep; 21 Suppl 2():S40-6. PubMed ID: 26206621
[TBL] [Abstract][Full Text] [Related]
3. Pan-European early switch/early discharge opportunities exist for hospitalized patients with methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections.
Nathwani D; Eckmann C; Lawson W; Stephens JM; Macahilig C; Solem CT; Simoneau D; Chambers R; Li JZ; Haider S
Clin Microbiol Infect; 2014 Oct; 20(10):993-1000. PubMed ID: 24673973
[TBL] [Abstract][Full Text] [Related]
4. European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid.
Bassetti M; Baguneid M; Bouza E; Dryden M; Nathwani D; Wilcox M
Clin Microbiol Infect; 2014 Apr; 20 Suppl 4():3-18. PubMed ID: 24580738
[TBL] [Abstract][Full Text] [Related]
5. Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria.
Eckmann C; Lawson W; Nathwani D; Solem CT; Stephens JM; Macahilig C; Simoneau D; Hajek P; Charbonneau C; Chambers R; Li JZ; Haider S
Int J Antimicrob Agents; 2014 Jul; 44(1):56-64. PubMed ID: 24928311
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant Staphylococcus aureus-complicated skin and soft tissue infections: a retrospective, propensity score-matched, case-control analysis.
Itani KM; Biswas P; Reisman A; Bhattacharyya H; Baruch AM
Clin Ther; 2012 Aug; 34(8):1667-73.e1. PubMed ID: 22770644
[TBL] [Abstract][Full Text] [Related]
7. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).
Itani KM; Weigelt J; Li JZ; Duttagupta S
Int J Antimicrob Agents; 2005 Dec; 26(6):442-8. PubMed ID: 16289514
[TBL] [Abstract][Full Text] [Related]
8. A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients.
McCollum M; Sorensen SV; Liu LZ
Clin Ther; 2007 Mar; 29(3):469-77. PubMed ID: 17577468
[TBL] [Abstract][Full Text] [Related]
9. Influence of real-world characteristics on outcomes for patients with methicillin-resistant Staphylococcal skin and soft tissue infections: a multi-country medical chart review in Europe.
Nathwani D; Eckmann C; Lawson W; Solem CT; Corman S; Stephens JM; Macahilig C; Simoneau D; Chambers R; Li JZ; Haider S
BMC Infect Dis; 2014 Sep; 14():476. PubMed ID: 25182029
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis.
Bounthavong M; Hsu DI
Curr Med Res Opin; 2010 Feb; 26(2):407-21. PubMed ID: 20001574
[TBL] [Abstract][Full Text] [Related]
11. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial.
Li JZ; Willke RJ; Rittenhouse BE; Rybak MJ
Surg Infect (Larchmt); 2003; 4(1):57-70. PubMed ID: 12744768
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus.
Itani KM; Dryden MS; Bhattacharyya H; Kunkel MJ; Baruch AM; Weigelt JA
Am J Surg; 2010 Jun; 199(6):804-16. PubMed ID: 20227056
[TBL] [Abstract][Full Text] [Related]
13. Early switch/early discharge opportunities for hospitalized patients with methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections in Brazil.
Furtado GH; Rocha J; Hayden R; Solem C; Macahilig C; Tang WY; Chambers R; Figueiredo MLN; Johnson C; Stephens J; Haider S
Braz J Infect Dis; 2019; 23(2):86-94. PubMed ID: 31078574
[TBL] [Abstract][Full Text] [Related]
14. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.
Stein GE; Wells EM
Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750
[TBL] [Abstract][Full Text] [Related]
15. Linezolid and vancomycin in treatment of lower-extremity complicated skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus in patients with and without vascular disease.
Duane TM; Weigelt JA; Puzniak LA; Huang DB
Surg Infect (Larchmt); 2012 Jun; 13(3):147-53. PubMed ID: 22568921
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue infections in France.
De Cock E; Sorensen S; Levrat F; Besnier JM; Dupon M; Guery B; Duttagupta S
Med Mal Infect; 2009 May; 39(5):330-40. PubMed ID: 19304423
[TBL] [Abstract][Full Text] [Related]
17. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.
Sharpe JN; Shively EH; Polk HC
Am J Surg; 2005 Apr; 189(4):425-8. PubMed ID: 15820454
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany.
Schürmann D; Sorensen SV; De Cock E; Duttagupta S; Resch A
Eur J Health Econ; 2009 Feb; 10(1):65-79. PubMed ID: 18437437
[TBL] [Abstract][Full Text] [Related]
19. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
McKinnon PS; Sorensen SV; Liu LZ; Itani KM
Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
[TBL] [Abstract][Full Text] [Related]
20. Pathophysiology and burden of infection in patients with diabetes mellitus and peripheral vascular disease: focus on skin and soft-tissue infections.
Dryden M; Baguneid M; Eckmann C; Corman S; Stephens J; Solem C; Li J; Charbonneau C; Baillon-Plot N; Haider S
Clin Microbiol Infect; 2015 Sep; 21 Suppl 2():S27-32. PubMed ID: 26198368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
